Physician profile
Cat T Dang
NPI 1992863955
$1,956.13
in general payments reported to CMS, 2019-2025
11 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $163 · 2021: $219 · 2022: $383 · 2023: $155 · 2024: $245 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $370.04 | 2020-2025 | Invega Sustenna |
| Alkermes, INC. | $340.25 | 2020-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $318.35 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $255.92 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $235.99 | 2022-2025 | Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $223.51 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Indivior INC. | $67.71 | 2020-2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.51 | 2020-2022 | |
| Tempus Ai, INC | $49.70 | 2024 | Tempus Pixel |
| Abbvie INC. | $24.81 | 2023 | Vraylar |
| Vanda Pharmaceuticals INC. | $17.34 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cat Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.